Single-dose pharmacokinetics, tolerability, and physiologically based pharmacokinetic modeling of Fazamorexant in Chinese patients with hepatic impairment and in healthy controls
ObjectivesYZJ-1139 (Fazamorexant) is a dual orexin receptor antagonist in development for adult insomnia. This study assessed the impact of hepatic impairment on Fazamorexant’s pharmacokinetic safety, and tolerability to guide clinical dosing.MethodsThis study used a non-randomized, open-label, sing...
Gardado en:
| Principais autores: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2026-04-01
|
| Series: | Frontiers in Pharmacology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1814155/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|